Drug Type AAV based gene therapy |
Synonyms- |
Target |
Mechanism FAH modulators(fumarylacetoacetate hydrolase modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization Vivet Therapeutics SASStartup |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Tyrosinemia, Type I | Preclinical | FR | Vivet Therapeutics SASStartup | 07 May 2024 |
Tyrosinemia, Type I | Preclinical | ES | 07 May 2024 |